Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
When SpaceX goes public…
It’s expected to be the biggest IPO in HISTORY…
As high as $1.5 TRILLION by some estimates.
That is an eye-watering amount of money…
And Wall Street insiders are salivating at the thought of SpaceX’s IPO.
But the best part…
You can get a piece of this SpaceX action before it goes public…in a regular brokerage account.
All thanks pre-IPO play almost no one’s talking about…
And if you act fast, you can get in position for LESS than $100.
Click here NOW for the full story.
But don’t wait…
As soon as word of this opportunity gets out, it could be too late…
And you could miss out on your chance to profit from the biggest IPO in history.
Click here before it’s too late.
Best,
Matt Insley
Publisher, Paradigm Press
Hinge Health's AI Moat Might Be Its Patient Movement Data
Author: Leo Miller. Originally Published: 2/23/2026.
Key Points
- PwC expects medical cost inflation to remain elevated, which strengthens the appeal of cost-reduction platforms like Hinge Health.
- Hinge’s MSK model is built to reduce therapy intensity and potentially avoid costly surgeries, supporting insurer adoption.
- Strong results are tempered by elevated stock-based compensation, though management expects SBC to normalize.
- Special Report: [Sponsorship-Ad-6-Format3]
The cost of healthcare in the United States is rising sharply. In its 2026 healthcare outlook, PricewaterhouseCoopers (PwC) highlighted the pressure of persistent inflationary forces on the system.
“The US healthcare system is heading into another year of powerful inflationary forces exerting pressure, with few deflationary forces in sight.” PwC estimates group insurance medical costs rose 8.5% in 2024, the fastest pace since 2012. It reports the same 8.5% increase in 2025 and expects another year of 8.5% growth in 2026.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
In that environment, Hinge Health (NYSE: HNGE), a mid-cap healthcare stock, deserves a closer look. Hinge's business model centers on cutting healthcare costs, and several large players are taking notice. Below is a breakdown of the fast-growing firm and its outlook after an impressive earnings report.
Understanding HNGE: Lowering Musculoskeletal Costs in Healthcare
Hinge Health focuses on one area of care: musculoskeletal (MSK) therapy. Its virtual MSK platform delivers personalized physical therapy programs patients can perform at home, accessed via a mobile app and supported by wearable devices, AI coaching, and human care teams.
Hinge says that in 2024 its platform reduced the number of human hours needed to support patients compared with traditional physical therapy by around 95%. Lower human-hour intensity helps drive down costs and is a key reason employers and insurers contract with Hinge.
For MSK conditions, the biggest cost driver is surgery. Hinge argues its platform reduces the likelihood patients will eventually need surgery by delivering timely, consistent intervention and lowering friction. Patients may find it easier to use Hinge's at-home program than to schedule and travel to in-person sessions, which can increase adherence to exercises and reduce downstream surgical risk.
One study of nearly 7,000 patients—about half using Hinge and half receiving traditional care—found the incidence of spinal fusion surgery was 56% lower among the Hinge group.
Insurers are taking notice. Hinge now works with over 2,800 self-insured corporations, representing 45% of Fortune 500 companies. It is also integrated with the U.S.'s five largest health plans, including UnitedHealth Group (NYSE: UNH), and the three largest pharmacy benefit managers, which helps lower the friction for new customers to join the platform.
Hinge Soars After Latest Earnings Report, But SBC Is Elevated
In its latest quarter, Hinge reported revenue of $171 million, up 46% year over year. Adjusted earnings per share rose 23% to $0.49. Both figures comfortably beat estimates, sending the stock up about 17% after the release. For 2026, the company projects full-year revenue growth of 25%, a marked deceleration from 2025's 51% growth. It expects adjusted operating margin to rise from 20% to 21%, and free cash flow surged in 2025 to $180 million—a roughly 300% increase over 2024.
One important caveat is stock-based compensation (SBC). SBC is a non-cash expense, but it represents real dilution and can mask the true cost of compensation when evaluating cash generation. Hinge's SBC expense totaled $643 million—more than three times the free cash flow it generated—so SBC materially distorts the picture of cash profitability.
On the positive side, Hinge expects SBC to decline significantly. The company projects SBC will average roughly $20 million to $25 million per quarter over the next four to eight quarters.
HNGE: An Intriguing AI Play on Healthcare
The MarketBeat consensus price target for Hinge Health is near $57, implying about 35% upside. Analyst targets updated after the earnings report average slightly lower, around $55, which still implies roughly 31% potential upside.
Hinge's model is gaining traction with insurers, and it may have a partial defense against AI-driven competition: proprietary data derived from patients' movement and program interactions. That dataset—built from real patient activity and outcomes—helps improve the product and would be difficult for competitors to replicate quickly.
The stock trades at a forward price-to-earnings ratio near 21x and has a market capitalization below $4 billion. While there are several reasons to consider Hinge as an attractive opportunity, investors should be prepared for potential volatility, particularly given lingering skepticism around software-oriented healthcare names.
Matador's Results Were Better Than Feared, But 2026 Headwinds Still Matter
Author: Thomas Hughes. Originally Published: 2/27/2026.
Key Points
- Matador is positioned as a quality Permian operator with a midstream cushion, steady cash flow, and ongoing capital returns despite a softer 2026 oil tape.
- Q4 2025 results and 2026 guidance are framed as better than feared, with production growth and lower spending supporting dividends and buybacks.
- The main near-term risk is institutional flow and technical resistance, which could cap upside and pressure shares before a longer-term rebound.
- Special Report: [Sponsorship-Ad-6-Format3]
Matador Resources (NYSE: MTDR) faces headwinds in 2026, including weak oil prices and softer market sentiment, but it remains a buy for long-term investors. This high-quality play on unconventional oil in West Texas and New Mexico continues to grow its business: expanding acreage, proven reserves, operating wells, and production, while generating positive cash flow and returning capital to shareholders. The key takeaway is that Matador is also improving asset quality, positioning itself for long-term success at current oil-price levels and for an accelerated earnings rebound if (when) oil recovers.
Insider activity highlights this company's quality. Insiders own nearly 6% of the stock and have been net buyers since the COVID-19 lows in 2020. While no purchases had been logged in 2026 as of late February, MarketBeat data shows insider buying ramped up in 2025 and reached record levels in Q4 2025.
Matador Reports Strength in Q4 2025; Issues Strong Guidance for 2026
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
Matador posted solid results for Q4 2025 despite lower oil prices. The company generated nearly $850 million in net revenue, down 12.6% year over year, and outpaced consensus by roughly 475 basis points. Production volume rose both year over year and sequentially, and midstream operations were a notable source of strength. The midstream business is important because it provides a steadier cash dividend tied to volumes rather than oil prices.
Margins held up better than feared. Operational execution produced positive cash flow on the production side, while midstream contributions exceeded expectations. Adjusted earnings were $0.87 per share—down more than 50% year over year but $0.11, or materially, better than analysts expected—supporting healthy cash flow, capital returns, and balance sheet improvement.
Guidance supports both growth and returns. Matador projects roughly 3% production growth and an 11% reduction in capital spending for 2026, which should create room for dividends and share buybacks.
Matador's dividend is substantial, yielding about 3% with the shares trading in the high-$40s, and is covered by roughly 25% of the 2026 earnings forecast. The company has raised the dividend seven times over the past five years and appears positioned to increase it again before year-end. Buybacks are also meaningful: Matador reduced its share count by 0.9% year over year in Q4 and is expected to continue repurchases.
Analysts and Institutions Cap Gains for MTDR in Early 2026
Analyst and institutional trends paint a mixed but broadly constructive picture. Fifteen analysts tracked by MarketBeat rate the stock as a Moderate Buy with a 73% buy-side bias, though many have trimmed price targets. Recent targets cluster near the low end of the range—potentially around $47—which may act as a near-term floor; the consensus still implies roughly 20% upside.
Institutional ownership is a larger near-term influence: institutions collectively own about 92% of the stock and were net accumulators through 2025. However, selling in Q1 2026 has outpaced buying, creating downward pressure. If that trend continues, MTDR could struggle to hold current levels and may revisit recent lows.
Price action reflects these headwinds. While there is evidence a bottom is in place, the early-2026 rebound stalled below the midpoint of the long-term trading range and ran into resistance around longer-term exponential moving averages. That technical setup suggests the stock remains under pressure and could test the $40 area by midyear.
The key question is whether institutions will shift back to buying at critical levels or whether price action will weaken further. A steep decline into the teens is not the base case, but it cannot be ruled out in a severe market downturn. At current valuations—trading at roughly 5x 2030 earnings forecasts—the shares look deeply undervalued relative to their potential, and positive execution by management could lift the stock. A potential catalyst in 2026 is the soon-to-open Hugh Brinson pipeline from Energy Transfer (NYSE: ET), which should connect Matador to the higher-priced Henry Hub market and improve realizations.
This message is a paid sponsorship from Paradigm Press, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you need assistance with your newsletter, please don't hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 North Reid Place #620, Sioux Falls, SD 57103-7078. USA..
No comments:
Post a Comment